Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension
- PMID: 9397246
- DOI: 10.1016/s0895-7061(97)00264-1
Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension
Abstract
The comparative effects of the once a day calcium channel antagonists amlodipine and long-acting diltiazem were assessed in a parallel design, investigator-blinded, multicenter trial in 123 patients with diastolic blood pressures ranging from 95 to 114 mm Hg before treatment. Patients were randomized to one of the two drugs and titrated at 2-week intervals to 5 or 10 mg of amlodipine or 180, 240, or 360 mg of long-acting diltiazem during a 10-week treatment period. Both drugs significantly reduced resting, sitting, standing, and 24-h ambulatory systolic and diastolic pressures. Amlodipine caused significantly greater reductions in sitting and standing systolic pressures, standing diastolic pressures, and 24-h ambulatory systolic and diastolic pressures versus diltiazem. Sitting systolic pressures were reduced from 151.9 +/- 2.0 (SE) at baseline to 137.9 +/- 1.8 mm Hg with amlodipine treatment and from 149.0 +/- 2.1 to 145.1 +/- 2.5 mm Hg with diltiazem. Sitting diastolic pressures were reduced from 100.2 +/- 0.6 to 87.8 +/- 1.0 mm Hg with amlodipine and from 101.1 +/- 1.0 to 91.9 +/- 1.1 mm Hg with diltiazem. Reductions in standing systolic pressures after treatment were -12.1 +/- 1.5 mm Hg amlodipine v -4.6 +/- 1.5 mm Hg diltiazem (P < .01), and reductions in standing diastolic pressures were -11.8 +/- 0.9 mm Hg amlodipine v -8.6 +/- 0.9 mm Hg diltiazem (P < .02). Heart rates did not change significantly with either drug during the study. Two subjects in each group dropped out because of adverse experiences. Although both agents were well tolerated and reduced blood pressures consistently over the 10-week test period, amlodipine was more effective than diltiazem in reducing systolic and diastolic blood pressures to the target pressures of < 140 mm Hg systolic and < 90 mm Hg diastolic over a range of doses widely used in clinical practice.
Similar articles
-
A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring.Blood Press. 1998 Jan;7(1):25-30. doi: 10.1080/080370598437538. Blood Press. 1998. PMID: 9551874 Clinical Trial.
-
Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.Clin Ther. 2006 Apr;28(4):537-51. doi: 10.1016/j.clinthera.2006.04.008. Clin Ther. 2006. PMID: 16750465 Clinical Trial.
-
Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial.J Assoc Physicians India. 2004 Mar;52:197-202. J Assoc Physicians India. 2004. PMID: 15636308 Clinical Trial.
-
Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension.Am J Med. 1992 Aug 31;93(2A):56S-64S. doi: 10.1016/0002-9343(92)90295-m. Am J Med. 1992. PMID: 1519637 Review.
-
Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.Can J Cardiol. 1997 Oct;13(10):914-20. Can J Cardiol. 1997. PMID: 9374947 Review.
Cited by
-
Amlodipine in the current management of hypertension.J Clin Hypertens (Greenwich). 2023 Sep;25(9):801-807. doi: 10.1111/jch.14709. Epub 2023 Aug 7. J Clin Hypertens (Greenwich). 2023. PMID: 37551050 Free PMC article. Review.
-
Psychological characteristics and responses to antihypertensive drug therapy.J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):25-34. doi: 10.1111/j.1524-6175.2002.00493.x. J Clin Hypertens (Greenwich). 2002. PMID: 11821634 Free PMC article. Clinical Trial.
-
A Novel High Content Angiogenesis Assay Reveals That Lacidipine, L-Type Calcium Channel Blocker, Induces In Vitro Vascular Lumen Expansion.Int J Mol Sci. 2022 Apr 28;23(9):4891. doi: 10.3390/ijms23094891. Int J Mol Sci. 2022. PMID: 35563280 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical